IN THE LITERATURE Is Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Combination Therapy Better Than Monotherapy and Safe in Patients With CKD?
暂无分享,去创建一个
[1] R. Townsend,et al. Is there added value to adding ARB to ACE inhibitors in the management of CKD? , 2009, Journal of the American Society of Nephrology : JASN.
[2] B. Rutkowski,et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[3] P. Zamboli,et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[4] G. Bakris,et al. Renin-angiotensin blockade and kidney disease , 2008, The Lancet.
[5] S. Yusuf,et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.
[6] J. McMurray. ACE inhibitors in cardiovascular disease--unbeatable? , 2008, The New England journal of medicine.
[7] S. Yusuf,et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.
[8] A. Kshirsagar,et al. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] U. Wenzel,et al. Aldosterone and progression of renal disease , 2008, Current opinion in nephrology and hypertension.
[10] R. Kunz,et al. Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the ReninAngiotensin System on Proteinuria in Renal Disease , 2008, Annals of Internal Medicine.
[11] J. Kalus,et al. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta‐analysis , 2007, Diabetic medicine : a journal of the British Diabetic Association.
[12] J. Craig,et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. , 2006, The Cochrane database of systematic reviews.
[13] K. Griffin,et al. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. , 2006, Clinical journal of the American Society of Nephrology : CJASN.
[14] H. Clark,et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[15] G. Becker,et al. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. , 2006, Clinical journal of the American Society of Nephrology : CJASN.
[16] Karl Swedberg,et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.
[17] Karl Swedberg,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.
[18] H. Morita,et al. RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial , 2003, The Lancet.
[19] J. Cohn,et al. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.
[20] C. Schmid,et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. , 2001, Kidney international.
[21] C. Schmid,et al. Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease , 2001, Annals of Internal Medicine.